Indaptus’s Decoy20 Platform Targets Cancer via Dual Immune Activation Approach
Indaptus unveils Decoy20, an innovative immunotherapy activating innate and adaptive immune responses in cancer.
Indaptus Therapeutics, a clinical-stage biotech company, recently shared a significant milestone in its cancer immunotherapy research. Dr. Michael Newman, Indaptus's founder and Chief Scientific Officer, published a study in Frontiers in Immunology that introduces the Decoy20 platform, an immunotherapy designed to simultaneously activate both innate and adaptive immune responses against cancer. The Decoy20 approach utilizes an innovative technique of killed, stabilized bacteria to stimulate multiple immune pathways, aiming to provide a comprehensive response against tumors with reduced toxicity. This multi-pathway approach stands apart from traditional single-target immunotherapies by aiming for broader immune activation, potentially resulting in a more durable response.
The Decoy20 platform showed promising results in preclinical studies, demonstrating efficacy against various tumor types. Its design—a transient "pulse-prime" approach—activates immune responses for short periods, aiming to strike a balance between broad activation and manageable toxicity levels. Dr. Newman emphasized the hope that Decoy20 can offer new possibilities for patients who haven’t responded well to conventional treatments.
Indaptus is now advancing Decoy20 into a Phase 1 clinical trial focused on several solid tumors. Additionally, through a partnership with BeiGene, the company plans to test Decoy20 in combination with BeiGene’s anti-PD-1 therapy, tislelizumab, in hopes of achieving even greater therapeutic effects. This collaboration is expected to provide new insights into Decoy20's efficacy and potential as a versatile cancer therapy.
This publication marks a notable achievement for Indaptus, underscoring its commitment to developing safer, more effective cancer treatments by leveraging immune system mechanisms in innovative ways. For Indaptus and its research team, this milestone brings excitement and optimism for the next steps in improving cancer care.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion